| Literature DB >> 33561935 |
Elisabeth Hodille1,2, Charlotte Genestet1,2, Thomas Delque1, Luna Ruffel1, Yvonne Benito1, Isabelle Fredenucci1, Jean-Philippe Rasigade1,2, Gérard Lina1,2, Oana Dumitrescu1,2.
Abstract
A rapid and reliable diagnostic for tuberculosis, including the detection of both rifampicin (RIF) and isoniazid (INH) resistance, is essential for appropriate patient care. Nucleic acid amplification tests are a fast alternative to methods based on Mycobacterium tuberculosis complex (MTB) cultures. Thus, the performance of the MDR/MTB ELITe MGB® Kit on the ELITe InGenius® platform was retrospectively evaluated for MTB detection on pulmonary and extra-pulmonary samples and for RIF/INH resistance detection on MTB strains. The sensitivity and specificity of the kit for MTB detection compared to the MTB culture were 80.0% and 100.0%, respectively. For the antimicrobial susceptibility prediction, the agreement with phenotypic antimicrobial susceptibility testing (AST) was 92.0%. For RIF, the sensitivity was 100.0% and the specificity was 95.5%. For INH, the sensitivity and specificity were 75.0% and 100.0%, respectively. A single RIF false-positive result was obtained for a strain with a low level of RIF resistance that was not detected by phenotypic AST, but carrying a rpoB L452P mutation. INH false-negative results (3) were due to mutations on the katG gene that were not probed by the test. Overall, the MTB/MDR ELITe MGB® Kit presents a strong performance for MTB detection and for the detection of both RIF and INH resistance, with an easy integration in laboratory workflow thanks to its fully automatized system.Entities:
Keywords: MTB/MDR ELITe MGB® Kit; Mycobacterium tuberculosis complex; Nucleic acid amplification test; multidrug-resistant tuberculosis; tuberculosis diagnosis
Year: 2021 PMID: 33561935 PMCID: PMC7914564 DOI: 10.3390/pathogens10020176
Source DB: PubMed Journal: Pathogens ISSN: 2076-0817